The introduction of novel drugs in multiple myeloma therapy has changed disease survivals
in last 15 years. Besides to be more effective in this disease new agents have been utilized in novel
strategies such as consolidation and maintenance therapy. Lenalidomide has been one of the favourite
in clinical trials because of its oral administration, and bortezomib has been utilized too after the drug
has been proved to be effective subcutaneously. Advances in the understanding of disease biology and
genetics could give a risk stratification to identify those patients who can benefit more and to better
drive maintenance therapy in the future.
Keywords: Bortezomib, chemotherapy, IMID's, myeloma, new agents.
Rights & PermissionsPrintExport